VITA LIFE SCIENCES LIMITED..
ASX:VLSPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 96.4% of what they think they own, once every option and right converts.
No major dilution pressure signals in current disclosures
VITA LIFE SCIENCES LIMITED ordinary share count stood at 54M as of September 2026. The company has not raised capital in the past 24 months and has no pending proposed securities issues. Options and rights on issue could convert into 2M new shares, representing 3.7% of the current share count, with none in the money at the current share price. An expiry date for these securities is not on record. The company does not have a current quarterly cash report on record, so no cash balance or funding runway figure is available. The share count series from ASX filings ends prior to the stated latest date, meaning share count change over the 24-month window is not stated.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 6 Sept 2026 | 3H · cancellation | VLS : ORDINARY FULLY PAID | 54.1M | Appendix 3H |
| 1 Sept 2026 | 3H · cancellation | VLS : ORDINARY FULLY PAID | 54.1M | Appendix 3H |
| 2 July 2026 | 3H · cancellation | VLS : ORDINARY FULLY PAID | 54.4M | Appendix 3H |
| 18 June 2026 | 2A · quoted issue | VLS : ORDINARY FULLY PAID | 54.4M | Appendix 2A |
| 8 June 2026 | 3G · unquoted | VLS : ORDINARY FULLY PAID | 54.2M | Appendix 3G |
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 2.0M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| VLSAD | Performance shares | Condition-triggered | — | — | 2.0M | Filing Meeting |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
A condition-triggered class has no exercise price and usually no expiry: what it vests on is set by a shareholder resolution, not by the register. Where the company lodged a notice of meeting before the class first appears here, it is linked as “Meeting” — that is where terms of this kind are put to shareholders. It is not confirmation that the document sets this class’s conditions, and no link appears where there is no such filing.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 1 Sept 2026 | Henry George Townsing | Sell off-market | — | — | — | — | 3Y notice |
| 9 June 2026 | Andrew O'Keefe | Other | 600k | — | — | $300k | 3Y notice |
| 1 June 2026 | Henry George Townsing | Sell | — | — | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.